KEY WORD INDEX

Adult T cell leukemia
Interleukin 2 receptor (Tac/L-chain); pX expression; Promoter activity; Post-transcriptional regulation (Kanamori, H., 293)

Aging
Interleukin 1; "Economic correction"; Epidermal immunity; Cytokines (Sauder, D. N., 111)

Alternative pathway activation
Complement; Factor D; Hemolysis; Immune complex solubilization (Sturfelt, G., 231)

Aluminium salt
Liposome; Immunological adjuvant; Muramyl dipeptide; Immune response (Gregoriadis, G., 237)

Amphotericin
N-Fru-Amb; Polyclonal lymphocyte activation (Henry-Toulmé, N., 63)

Anti-DNA-histone
Systemic lupus erythematosus; LE cell; MRL mice; Feulgen reaction (Kanai, Y., 9)

Anti-Tac
Interleukin 2 receptor; Interleukin 2; Expression cloning; FACS (Minamoto, S., 139)

Antibodies
Endothelial cells; Mixed connective tissue disease; Organ damage (Bodolay, E., 163)

Antigens
CD1; CD3; Diagnostic potential (Lowe, J., 103)

Antigens
Endothelium; Monocytes; Lymph node; Immunohistochemistry (Facchetti, F., 277)

Atherosclerosis, human
C5b-9 complement complex; Macrophage (Rus, H. G., 305)

Autoimmunity
Epstein Barr Virus; Molecular mimicry; Rheumatoid Arthritis (Sulitzeanu, D., 89)

B cell deletion
Experimental autoimmune thyroiditis; Thyroglobulin autoantibody (Rayfield, L. S., 21)

B cell differentiation
Chronic type B-lymphocytic leukemia; Low affinity Fc receptor; Interleukin 4; Soluble FcεRII (Ishida, H., 323)

B lymphoblastoid cell lines
RhuGM-CSF; Normal B cells; Normal B cell enrichment (Haas, R., 133)

BLT-esterase
T cell line; Interleukin 1; Fetal calf serum (Schlegel-Haueter, S. E., 35)

BMDM
Bone marrow derived macrophage; Electron energy loss spectroscopy (EELS) (Wolf, B., 121)

Bb-receptor
Complement; Monocytes; Macrophages (Saeki, T., 97)

Bf
Complement and aging; C2; C4 (Kramer, J., 83)

Bloodstream trypomastigotes
Trypanosoma cruzi; Phagocytic activity; Culture trypomastigotes (Camargo, I. J. B., 213)

Bone marrow derived macrophage
BMDM; Electron energy loss spectroscopy (EELS) (Wolf, B., 121)

Bovine leukemia virus
CD5 antigen; Monoclonal antibody (Depelchin, A., 69)

C2
Complement and aging; C4; Bf (Kramer, J., 83)

C4
Complement and aging; C2; Bf (Kramer, J., 83)

C5b-9 complement complex
Macrophage; Atherosclerosis, human (Rus, H. G., 305)

CD1
Antigens; CD3; Diagnostic potential (Lowe, J., 103)

CD11c antigen
Superoxide anion; U-937 cell line (Cabañas, C., 193)

CD3
Antigens; CD1; Diagnostic potential (Lowe, J., 103)

CD3 antigen
Calcium signal; T cells; Jurkat; Protein kinase C; Phorbol ester (Tordai, A., 47)

CD5 antigen
Bovine leukemia virus; Monoclonal antibody (Depelchin, A., 69)

CH2, CH3 domains
IgG-binding; Fc receptors (Gergely, J., 1)

CTL
Limiting dilutions; IL-2; LAK cells (Leshem, B., 53)

CTL
Cytolytic T lymphocytes; Ca^{2+} in lymphocytotoxicity; Prelytic events in lymphocytotoxicity; Mechanisms of lymphocytotoxicity; Perforin; Lytic granules (Berke, G., 169)

Ca^{2+} in lymphocytotoxicity
Cytolytic T lymphocytes; CTL; Prelytic events in lymphocytotoxicity; Mechanisms of lymphocytotoxicity; Perforin; Lytic granules (Berke, G., 169)

Calcium signal
T cells; Jurkat; Protein kinase C; Phorbol ester; CD3 antigen (Tordai, A., 47)

Campylobacter
IgG; Gastritis (Van Bohemen, Ch. G., 59)

Cecropin D
Suppression; Hemopoietic cells (Okai, Y., 127)

Chronic type B-lymphocytic leukemia
B cell differentiation; Low affinity Fc receptor; Interleukin 4; Soluble FcεRII (Ishida, H., 323)
Circadian rhythm
IL-2; Human lymphocytes (Smith, C., 15)
Complement and aging
C2; C4; Bf (Kramer, J., 83)
Complement
Bb-receptor; Monocytes; Macrophages (Saeki, T., 97)
Complementary peptide
Opioid receptor; Monoclonal antibody; Neuroimmunology (Carr, D. J. J., 181)
Complement
Factor D; Alternative pathway activation; Hemolysis; Immune complex solubilization (Sturfelt, G., 231)
Cord blood
T cell proliferation; Cytokine; HLA-DR (Hurme, M., 217)
Cross-linking
Interleukin 2 receptor; High- and low-affinity binding of interleukin 2; Monoclonal antibodies (Osawa, H., 205)
Cross-reactivity
In vitro immunization; Natural antibodies; Multispecificity; Monoclonal antibodies (Borrebaeck, C. A. K., 255)
Culture trypomastigotes
Trypanosoma cruzi; Phagocytic activity; Bloodstream trypomastigotes (Camargo, I. J. B., 213)
Cytokine
T cell proliferation; Cord blood; HLA-DR (Hurme, M., 217)
Cytokines
Interleukin 1; Aging; "Economic correction"; Epidermal immunity (Sauder, D. N., 111)
Cytolytic T lymphocytes
CTL; Ca^{2+} in lymphocytotoxicity; Prelytic events in lymphocytotoxicity; Mechanisms of lymphocytotoxicity; Perforin; Lytic granules (Berke, G., 169)

Diagnostic potential
Antigens; CD1; CD3 (Lowe, J., 103)

EBV-immortalized B cells
LAK cells (Kundu, S. K., 299)
"Economic correction"
Interleukin 1; Aging; Epidermal immunity; Cytokines (Sauder, D. N., 111)
Electron energy loss spectroscopy (EELS)
BMDM; Bone marrow derived macrophage (Wolf, B., 121)
Endothelial cells
Antibodies; Mixed connective tissue disease; Organ damage (Bodolay, E., 163)
Endothelium
Monocytes; Antigens; Lymph node; Immunohistochemistry (Facchetti, F., 277)
Epidermal immunity
Interleukin 1; Aging; "Economic correction"; Cytokines (Sauder, D. N., 111)
Epstein Barr Virus
Molecular mimicry; Rheumatoid Arthritis; Autoimmunity (Sulitzeanu, D., 89)
Esculetin
T cell activation; Interleukin 2 (Kabelitz, D., 241)

Experimental autoimmune thyroiditis
Thyroglobulin autoantibody; B cell deletion (Rayfield, L. S., 21)
Expression cloning
Interleukin 2 receptor; Anti-Tac; Interleukin 2; FACS (Minamoto, S., 139)

FACS
Interleukin 2 receptor; Anti-Tac; Interleukin 2; Expression cloning (Minamoto, S., 139)
Factor D
Complement; Alternative pathway activation; Hemolysis; Immune complex solubilization (Sturfelt, G., 231)
Fc receptors
IgG-binding; CH2, CH3 domains (Gergely, J., 1)
Fc receptor
Interleukin 1; TNF; Macrophage; Ganglioside (Hoon, D. S. B., 269)
Fetal calf serum
Insulin-like growth factor-1 (IGF-1); Mitogenic response; Human peripheral blood mononuclear cells (Roldan, A., 5)
Fetal calf serum
T cell line; BLT-esterase; Interleukin 1 (Schlegel-Haueter, S. E., 35)
Feulgen reaction
Systemic lupus erythematosus; LE cell; Anti-DNA-histone; MRL mice (Kanai, Y., 9)
Fibroblast-derived peptide
Suppression; Human PMNs (Okai, Y., 41)

Ganglioside
Interleukin 1; TNF; Fc receptor; Macrophage (Hoon, D. S. B., 269)
Gastritis
IgG; *Campylobacter* (Van Bohemen, Ch. G., 59)

HIV-1 antigenemia
Neutralizing antibody; Relationship (Sei, Y., 223)
HLA-DR
T cell proliferation; Cord blood; Cytokine (Hurme, M., 217)
Helper T cells
Myasthenia gravis; Hybridoma clones; Synthetic peptides; Immunodominance (Pachner, A. R., 199)
Hemolysis
Complement; Factor D; Alternative pathway activation; Immune complex solubilization (Sturfelt, G., 231)
Hemopoietic cells
Suppression; Cecropin D (Okai, Y., 127)
High- and low-affinity binding of interleukin 2
Interleukin 2 receptor; Cross-linking; Monoclonal antibodies (Osawa, H., 205)
Human PMNs
Fibroblast-derived peptide; Suppression (Okai, Y., 41)
Human T cell clones
Lymphokine secretion; Tolerisation in vitro (Pawelec, G., 187)
Human lymphocyte
IL-2; Circadian rhythm (Smith, C., 15)
Human peripheral blood mononuclear cells
Insulin-like growth factor-1 (IGF-1); Mitogenic response; Fetal calf serum (Roldan, A., 5)

Hybridoma clones
Myasthenia gravis; Helper T cells; Synthetic peptides; Immunodominance (Pachner, A. R., 199)
Hybridoma cell adherence
NK activity; Vitamin D (Najbauer, J., 317)

IgG
Campylobacter; Gastritis (Van Bohemen, Ch. G., 59)
IgG-binding
Fc receptors; CH2, CH3 domains (Gergely, J., 1)
IL-2
Circadian rhythm; Human lymphocyte (Smith, C., 15)
IL-2
Limiting dilutions; CTL; LAK cells (Leshem, B., 53)
IL-4
IL-2; Interferon gamma production; T helper cell subsets (Dohlsten, M., 29)
IL-2 production
OKT3 activation (Andersson, U., 115)
Immune complex solubilization
Complement; Factor D; Alternative pathway activation; Hemolysis (Sturfelt, G., 231)
Immune response
Liposome; Immunological adjuvant; Aluminium salt; Muramyl dipeptide (Gregoriadis, G., 237)
Immunodominance
Myasthenia gravis; Helper T cells; Hybridoma clones; Synthetic peptides (Pachner, A. R., 199)
Immunohistochemistry
Endothelium; Monocytes; Antigens; Lymph node (Facchetti, F., 277)
Immunological adjuvant
Liposome; Aluminium salt; Muramyl dipeptide; Immune response (Gregoriadis, G., 237)
Immunopotentiation
Immunosenescence; 2-Mercaptoethanol; T blast cells; Protein kinase C (Fong, T. C., 149)
Immunosenescence
Immunopotentiation; 2-Mercaptoethanol; T blast cells; Protein kinase C (Fong, T. C., 149)
Immunosuppressor factor
Pre-implantation embryo; Pregnancy (Bose, R., 261)
Immunotoxin
Tumor-bearing animals; Survival time (Mota, G., 283)
In vitro immunization
Natural antibodies; Cross-reactivity; Multispecificity; Monoclonal antibodies (Borrebaeck, C. A. K., 255)
Inhibitors of transcription
Monocytes; Tumor necrosis factor (Voitenok, N. N., 77)
Insulin-like growth factor-1 (IGF-1)
Mitogenic response; Human peripheral blood mononuclear cells; Fetal calf serum (Roldan, A., 5)
Interferon gamma production
IL-2; IL-4; T helper cell subsets (Dohlsten, M., 29)
Interleukin 1
T cell line; BLT-esterase; Fetal calf serum (Schlegel-Haueter, S. E., 35)
Interleukin 1
Aging; "Economic correction"; Epidermal immunity; Cytokines (Sauder, D. N., 111)
Interleukin 1
TNF; Fc receptor; Macrophage; Ganglioside (Hoon, D. S. B., 269)
Interleukin 2
Interleukin 2 receptor; Anti-Tac; Expression cloning; FACS (Minamoto, S., 139)
Interleukin 2
T cell activation; Esculetin (Kabelitz, D., 241)
Interleukin 2 receptor
Anti-Tac; Interleukin 2; Expression cloning; FACS (Minamoto, S., 139)
Interleukin 2 receptor
High- and low-affinity binding of interleukin 2; Cross-linking; Monoclonal antibodies (Osawa, H., 205)
Interleukin 2 receptor (Tac/L-chain)
Adult T cell leukemia; pX expression; Promoter activity; Post-transcriptional regulation (Kanamori, H., 293)
Interleukin 4
B cell differentiation; Chronic type B-lymphocytic leukemia; Low affinity Fc receptor; Soluble FcεRII (Ishida, H., 323)

Jurkat
Calcium signal; T cells; Protein kinase C; Phorbol ester; CD3 antigen (Tordai, A., 47)

LAK cells
Limiting dilutions; IL-2; CTL (Leshem, B., 53)
LAK cells
EBV-immortalized B cells (Kundu, S. K., 299)
LE cell
Systemic lupus erythematosus; Anti-DNA-histone; MRL mice; Feulgen reaction (Kanai, Y., 9)
Limiting dilutions
IL-2; CTL; LAK cells (Leshem, B., 53)
Liposome
Immunological adjuvant; Aluminium salt; Muramyl dipeptide; Immune response (Gregoriadis, G., 237)
Low affinity Fc receptor
B cell differentiation; Chronic type B-lymphocytic leukemia; Interleukin 4; Soluble FcεRII (Ishida, H., 323)
Lymph node
Endothelium; Monocytes; Antigens; Immunohistochemistry (Facchetti, F., 277)
Lymphokine secretion
Human T cell clones; Tolerization in vitro (Pawelec, G., 187)
Lytic granules
Cytolytic T lymphocytes; CTL; Ca^{2+} in lymphocytotoxicity; Prelytic events in lymphocytotoxicity; Mechanisms of lymphocytotoxicity; Perforin (Berke, G., 169)

MRL mice
Systemic lupus erythematosus; LE cell; Anti-DNA-histone; Feulgen reaction (Kanai, Y., 9)
Macrophages
Complement; Bb-receptor; Monocytes (Saeki, T., 97)
Macrophage
Interleukin 1; TNF; Fc receptor; Ganglioside (Hoon, D. S. B., 269)

Macrophage
C5b-9 complement complex; Atherosclerosis, human (Rus, H. G., 305)
Mechanisms of lymphocytotoxicity
Cytolytic T lymphocytes; CTL; Ca^{2+} in lymphocytotoxicity; Prelytic events in lymphocytotoxicity; Perforin; Lytic granules (Berke, G., 169)
2-Mercaptoethanol
Immunosenescence; Immunopotentiation; T blast cells; Protein kinase C (Fong, T. C., 149)
Mitogenic response
Insulin-like growth factor-1 (IGF-1); Human peripheral blood mononuclear cells; Fetal calf serum (Roldan, A., 5)
Mixed connective tissue disease
Antibodies; Endothelial cells; Organ damage (Bodolay, E., 163)
Molecular mimicry
Epstein Barr Virus; Rheumatoid Arthritis; Autoimmunity (Sulitzeanu, D., 89)
Monoclonal antibody
Bovine leukemia virus; CD5 antigen (Depelchin, A., 69)
Monoclonal antibody
Opioid receptor; Complementary peptide; Neuroimmunology (Carr, D. J. J., 181)
Monoclonal antibodies
Interleukin 2 receptor; High- and low-affinity binding of interleukin 2; Cross-linking (Osawa, H., 205)
Monoclonal antibodies
In vitro immunization; Natural antibodies; Cross-reactivity; Multispecificity (Borrebaeck, C. A. K., 255)
Monocytes
Tumor necrosis factor; Inhibitors of transcription (Voitenok, N. N., 77)
Monocytes
Complement; Bb-receptor; Macrophages (Saeki, T., 97)
Monocytes
Endothelium; Antigens; Lymph node; Immunohistochemistry (Facchetti, F., 277)
Mononuclear phagocytes
Viability; Substratum (Gregory, S. H., 155)
Multispecificity
In vitro immunization; Natural antibodies; Cross-reactivity; Monoclonal antibodies (Borrebaeck, C. A. K., 255)
Muramyl dipeptide
Liposome; Immunological adjuvant; Aluminium salt; Immune response (Gregoriadis, G., 237)
Myasthenia gravis
Helper T cells; Hybridoma clones; Synthetic peptides; Immunodominance (Pachner, A. R., 199)

N-Fru-Amb
Amphotericin; Polyclonal lymphocyte activation (Henry-Toulmé, N., 63)
NK activity
Hybridoma cell adherence; Vitamin D (Najbauer, J., 317)
NK cell cytotoxicity
Resistance to NK lysis; Tumour factor (Serrano, R., 311)
Natural antibodies
In vitro immunization; Cross-reactivity; Multispecificity; Monoclonal antibodies (Borrebaeck, C. A. K., 255)
Neuroimmunology
Opioid receptor; Monoclonal antibody; Complementary peptide (Carr, D. J. J., 181)
Neutralizing antibody
HIV-1 antigenemia; Relationship (Sei, Y., 223)
Normal B cells
RhuGM-CSF; B lymphoblastoid cell lines; Normal B cell enrichment (Haas, R., 1337)
Normal B cell enrichment
RhuGM-CSF; Normal B cells; B lymphoblastoid cell lines (Haas, R., 133)

OKT3 activation
IL-2 production (Andersson, U., 115)
Opioid receptor
Monoclonal antibody; Complementary peptide; Neuroimmunology (Carr, D. J. J., 181)
Organ damage
Antibodies; Endothelial cells; Mixed connective tissue disease (Bodolay, E., 163)

pX expression
Interleukin 2 receptor (Tac/L-chain); Adult T cell leukemia; Promoter activity; Post-transcriptional regulation (Kanamori, H., 293)
Perforin
Cytolytic T lymphocytes; CTL; Ca^{2+} in lymphocytotoxicity; Prelytic events in lymphocytotoxicity; Mechanisms of lymphocytotoxicity; Lytic granules (Berke, G., 169)
Phagocytic activity
Trypanosoma cruzi; Bloodstream trypomastigotes; Culture trypomastigotes (Camargo, I. J. B., 213)
Phorbol ester
Calcium signal; T cells; Jurkat; Protein kinase C; CD3 antigen (Tordai, A., 47)
Polyclonal lymphocyte activation
Amphotericin; N-Fru-Amb (Henry-Toulmé, N., 63)
Post-transcriptional regulation
Interleukin 2 receptor (Tac/L-chain); Adult T cell leukemia; pX expression; Promoter activity (Kanamori, H., 293)
Pre-implantation embryo
Immunosuppressor factor; Pregnancy (Bose, R., 261)
Pregnancy
Immunosuppressor factor; Pre-implantation embryo (Bose, R., 261)
Prelytic events in lymphocytotoxicity
Cytolytic T lymphocytes; CTL; Ca^{2+} in lymphocytotoxicity; Mechanisms of lymphocytotoxicity; Perforin; Lytic granules (Berke, G., 169)
Promoter activity
Interleukin 2 receptor (Tac/L-chain); Adult T cell leukemia; pX expression; Post-transcriptional regulation (Kanamori, H., 293)
Protein kinase C
Calcium signal; T cells; Jurkat; Phorbol ester; CD3 antigen (Tordai, A., 47)
Protein kinase C
Immunosenescence; Immunopotentiation; 2-Mercaptoethanol; T blast cells (Fong, T. C., 149)

Relationship
HIV-1 antigenemia; Neutralizing antibody (Sei, Y., 223)
Resistance to NK lysis
NK cell cytotoxicity; Tumour factor (Serrano, R., 3117)
Rheumatoid Arthritis
Epstein Barr Virus; Molecular mimicry; Autoimmunity (Sulitzeanu, D., 89)
RhuGM-CSF
Normal B cells; B lymphoblastoid cell lines; Normal B cell enrichment (Haas, R., 133)

Soluble FcεRII
B cell differentiation; Chronic type B-lymphocytic leukemia; Low affinity Fc receptor; Interleukin 4 (Ishida, H., 323)
Substratum
Viability; Mononuclear phagocytes (Gregory, S. H., 155)
Superoxide anion
CD11c antigen; U-937 cell line (Cabañas, C., 193)
Suppression
Fibroblast-derived peptide; Human PMNs (Okai, Y., 41)
Suppression
Cecropin D; Hemopoietic cells (Okai, Y., 127)
Survival time
Immunotoxin; Tumor-bearing animals (Moţa, G., 283)
Synthetic peptides
Myasthenia gravis; Helper T cells; Hybridoma clones; Immunodominance (Pachner, A. R., 199)
Systemic lupus erythematosus
LE cell; Anti-DNA-histone; MRL mice; Feulgen reaction (Kanai, Y., 9)

T blast cells
Immunosenescence; Immunopotentiation; 2-Mercaptoethanol; Protein kinase C (Fong, T. C., 149)
T cell activation
Esculetin; Interleukin 2 (Kabelitz, D., 241)
T cell line
BLT-esterase; Interleukin 1; Fetal calf serum (Schlegel-Haueter, S. E., 35)
T cell proliferation
Cord blood; Cytokine; HLA-DR (Hurme, M., 217)
T cells
Calcium signal; Jurkat; Protein kinase C; Phorbol ester; CD3 antigen (Tordai, A., 47)
T helper cell subsets
IL-2; IL-4; Interferon gamma production (Dohlsten, M., 29)
TNF
Interleukin 1; Fc receptor; Macrophage; Ganglioside (Hoon, D. S. B., 269)
Thyroglobulin autoantibody
Experimental autoimmune thyroiditis; B cell deletion (Rayfield, L. S., 21)
Tolerisation in vitro
Lymphokine secretion; Human T cell clones (Pawelec, G., 187)
Trypanosoma cruzi
Phagocytic activity; Bloodstream trypomastigotes; Culture trypomastigotes (Camargo, I. J. B., 213)
Tumor necrosis factor
Monocytes; Inhibitors of transcription (Voitenok, N. N., 77)
Tumor-bearing animals
Immunotoxin; Survival time (Moţa, G., 283)
Tumour factor
NK cell cytotoxicity; Resistance to NK lysis (Serrano, R., 3117)

U-937 cell line
Superoxide anion; CD11c antigen (Cabañas, C., 193)

Viability
Mononuclear phagocytes; Substratum (Gregory, S. H., 155)
Vitamin D
NK activity; Hybridoma cell adherence (Najbauer, J., 317)

AUTHOR INDEX

Aebischer, F., see Schlegel-Haueter, S. E., 35
Ali Al-Gorany, K. H., see Kabelitz, D., 241
Allison, A. C., see Roldan, A., 5
Alonso, C., see Serrano, R., 311
Anafi, M., see Sulitzeanu, D., 89
Andersson, U. and Sander, B., Detection of individual interleukin 2-producing cells after anti-CD3 antibody activation, 115
Andrews, S. J., see Rayfield, L. S., 21
Arai, N., see Ishida, H., 323
Atassi, M. Z., see Pachner, A. R., 199

Bancu, A., see Moţa, G., 283
Bekesi, J. G., see Sei, Y., 223
Bergmeier, L. A., see Rayfield, L. S., 21
Berke, G., Response to comment by Nabholz and Tschopp on Minireview (p. 169) 323
Berke, G., The cytolytic T lymphocyte and its mode of action, 169
Bernabeu, C., see Cabañas, C., 193
Bessler, W. G., see Wolf, B., 121
Blalock, J. E., see Carr, D. J. J., 181
Bodolay, E., Bojan, F., Szegedi, G., Stenszky, V. and Farid, N. R., Cytotoxic endothelial cell antibodies in mixed connective tissue disease, 163
Bojan, F., see Bodolay, E., 163
Borrebaeck, C. A. K. and Glad, C., Cross-reactivity of mouse monoclonal antibodies produced by in vitro or in vivo immunization, 255
Bose, R., Human embryo associated immunosuppressor factor(s) from pre- and post-implantation stages share some similarities, 261
Bost, K. L., see Carr, D. J. J., 181
Brown, B., see Lowe, J., 103
Burny, A., see Depelchin, A., 69
Busch, F. W., see Pawelec, G., 187

Cabañas, C., Lacal, P., Mollinedo, F., López-Rivas, A., Sánchez-Madrid, F. and Bernabeu, C., A monoclonal antibody to CD11c antigen inhibits the production of superoxide anion induced by concanavalin A in PMA-differentiated U-937 cells, 193
Camargo, I. J. B., Sakurada, J. K., Zucato, M. R. L., De Araújo, P. M. F. and De Araújo Rangel, H., The early phase of the immune response of CBA mice infected with *Trypanosoma cruzi* 213
Carlsson, R., see Dohlsten, M., 29
Carr, D. J. J., Blalock, J. E. and Bost, K. L., Monoclonal antibody against a peptide specified by [Met]-enkephalin complementary RNA recognizes the delta-class opioid receptor, 181
Charreau, E., see Roldan, A., 5
Chu, F. N., see Sei, Y., 223
Cinader, B., see Sauder, D. N., 111
Cochran, A. J., see Hoon, D. B. S., 269

De Araújo Rangel, H., see Camargo, I. J. B., 213
De Araújo, P. M. F., see Camargo, I. J. B., 213
De Wolf-Peeters, C., see Facchetti, F., 277
Depelchin, A., Letesson, J. J., Lostrie-Trussart, N., Mammerickx, M., Portetelle, D. and Burny, A., Bovine leukemia virus (BLV)-infected B-cells express a marker similar to the CD5 T cell marker, 69
Desmet, V. J., see Facchetti, F., 277
Diamantstein, T., see Osawa, H., 205
Dohlsten, M., Hedlund, G., Fischer, H., Sjögren, H. O. and Carlsson, R., Proliferation of human $CD4^+45R^+$ and $CD4^+45R^-$ T helper cells is promoted by both IL-2 and IL-4 while interferon-gamma production is restricted to IL-2 activated $CD4^+45R^-$ T cells, 29
Doi, T., see Minamoto, S., 139

Epstein, E., see Leshem, B., 53
Eugui, E. M., see Roldan, A., 5

Facchetti, F., De Wolf-Peeters, C., Van den Oord, J. J., Meijer, C. J. L. M., Pals, S. T. and Desmet, V. J., Anti-high endothelial venule monoclonal antibody HECA-452 recognizes plasmacytoid T cells and delineates an "extranodular" compartment in the reactive lymph node, 277
Farid, N. R., see Bodolay, E., 163
Fischer, H., see Dohlsten, M., 29
Fong, T. C. and Makinodan, T., Preferential enhancement by 2-mercaptoethanol of IL-2 responsiveness of T blast cells from old over young mice is associated with potentiated protein kinase C translocation, 149
Fridman, W. H., Sautès, C. and Teillaud, J. L., Immunoglobulin-binding factors, 249
Füst, G., see Kramer, J., 83

Gergely, J. and Sarmay, G., IgG-Fc-receptors: ligand binding and lysis induction, 1
Ghiurca, V., see Rus, H. G., 305
Glad, C., see Borrebaeck, C. A. K., 255
Gregoriadis, G. and Panagiotidi, C., Immunoadjuvant action of liposomes: comparison with other adjuvants, 237

Gregory, S. H., The viability of monoclonal phagocytes in vitro is diminished by the interaction of cells with serum proteins bound to the culture substratum, 155
Gárdos, G., see Tordai, A., 47
Görög, Gy., see Tordai, A., 47

Haas, R., Hohaus, S., Kiesel, S., Ogniben, E. and Hunstein, W., Effect of recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) on normal peripheral B lymphocytes and B lymphoblastoid cell lines, 133
Hardie, D., see Lowe, J., 103
Hashiba-Kanai, Y., see Kanai, Y., 9
Hatakeyama, M., see Minamoto, S., 139
Hauschildt, S., see Wolf, B., 121
Hedlund, G., see Dohlsten, M., 29
Henry-Toulmé, N., Hermier, B. and Seman, M., Immunomodulating properties of the *N*-(1-deoy-D-fructos-lyl) derivative of Amphotericin B in mice, 63
Hermier, B., see Henry-Toulmé, N., 63
Hohaus, S., see Haas, R., 133
Honjo, T., see Kanamori, H., 293
Hoon, D. B. S., Jung, T., Naungayan, J., Cochran, A. J., Morton, D. L. and McBride, W. H., Modulation of human macrophage functions by gangliosides, 269
Hunstein, W., see Haas, R., 133
Hurme, M. and Sihvola, M., Cytokine modulation of HLA-DR expression on proliferating cord blood T cells, 217

Imura, H., see Ishida, H., 323
Ishida, H., Kumagai, S., Iwai, K., Takahashi, T., Kawabe, T., Yodoi, J., Arai, N., Namiuchi, S., Konaka, Y. and Imura, H., Heterogeneity in terms of interleukin 4 dependent regulation of Fcε receptor/CD23 expression on chronic B-lymphocytic leukemia cells, 323
Ishida, N., see Kanamori, H., 293
Itoh, S., see Minamoto, S., 139
Iwai, K., see Ishida, H., 323

Jung, G., see Wolf, B., 121
Jung, T., see Hoon, D. B. S., 269

Kabelitz, D. and Ali Al-Gorany, K. H., Esculetin inhibits T cell activation without suppressing IL-2 production or IL-2 production of IL-2 receptor expression, 241
Kanai, Y., Yamauchi, S. and Hashiba-Kanai, Y., Lupus erythematosus cell formation by a monoclonal antibody derived from an autoimmune MRL/Mp-lpr/lpr mouse, 9
Kanamori, H., Suzuki, N., Ishida, N. and Honjo, T., Transcriptional regulation alone does not explain the constitutive expression of the interleukin 2 receptor (Tac/L-chain) in HTLV-1 infected cells, 293
Kantor, F. S., see Pachner, A. R., 199
Kawabe, T., see Ishida, H., 323
Kedar, E., see Leshem, B., 53
Kiesel, S., see Haas, R., 133
Kolesnikova, T., see Voitenok, N. N., 77
Konaka, Y., see Ishida, H., 323
Kono, T., see Minamoto, S., 139
Kramer, J., Rajczy, K. and Füst, G., Low incidence of null alleles of the fourth component of complement (C4) in elderly people, 83
Kumagai, S., see Ishida, H., 323
Kundu, S. K. and Menezes, J., Interleukin-2 induced killer cell activity against Epstein-Barr virus-immortalized human B cells, 299

Lacal, P., see Cabañas, C., 193
Langenberg, M. L., see Van Bohemen, Ch. G., 59
Leshem, B., Epstein, E. and Kedar, E., Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor, 53
Letesson, J. J., see Depelchin, A., 69
Ling, N., see Lowe, J., 103
Lostrie-Trussart, N., see Depelchin, A., 69
Lowe, J., Brown, B., Hardie, D., Richardson, P. and Ling, N., Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia, 103
López-Rivas, A., see Cabañas, C., 193

Makinodan, T., see Fong, T. C., 149
Mammerickx, M., see Depelchin, A., 69
Marcheş, R., see Moţa, G., 283
Mărgineanu, M., see Moţa, G., 283
McBride, W. H., see Hoon, D. B. S., 269
Meijer, C. J. L. M., see Facchetti, F., 277
Menezes, J., see Kundu, S. K., 299
Metzger, J., see Wolf, B., 121
Minamoto, S., Itoh, S., Kono, T., Doi, T. and Hatakeyama, M., Ligand-dependent selection of the receptor gene: segregation of IL-2 binding activity and anti-Tac reactivity by a single amino acid alteration in the Tac antigen (p55), 139
Misuno, N. I., see Voitenok, N .N., 77
Mollinedo, F., see Cabañas, C., 193
Monserrat, J., see Serrano, R., 311
Moraru, I., see Moţa, G., 283
Morton, D. L., see Hoon, D. B. S., 269
Moţa, G., Mărgineanu, M., Marcheş, R., Nicolae, M., Bancu, A. and Moraru, I., Experimental model for testing the efficiency of immunotoxins administered in vivo: evaluation of two ricin A-chain – multivalent antibody immunotoxins, 283
Mulac-Jericevic, B., see Pachner, A. R., 199
Muñoz, J., see Serrano, R., 311

Nabholz, M. and Tschopp, J., CTL-mediated cytolysis: perforin and alternative pathways?, 179
Nagasawa, S., see Saeki, T., 97
Najbauer, J., Szekeres-Bartho, J. and Tigyi, G. J., Modulation of cell – cell and cell – antigen interactions by 1,25-dihydroxyvitamin D3 and vitamin D3 sulfate in vitro: a study on pregnancy lymphocytes and hybridoma cells, 317
Namiuchi, S., see Ishida, H., 323
Naungayan, J., see Hoon, D. B. S., 269

Nicolae, M., see Moţa, G., 283
Niculescu, F., see Rus, H. G., 305

Ogniben, E., see Haas, R., 133
Okai, Y. and Qu, X-m., Effects of a purified cecropin D from a Chinese silk moth on growth, function and differentiation of murine hemopoietic cells, 127
Okai, Y., A human embryo fibroblast-derived peptide suppresses the zymosan-induced biochemical activation in human polymorphonuclear leukocytes, 41
Osawa, H. and Diamantstein, T., Studies on the formation of high-affinity IL-2 binding sites of an IL-2 receptor p55 + p75 heterodimeric complex: functional importance of a determinant on the p55 subunit defined by a monoclonal antibody AHT-107, 205
Oudbier, J., see Van Bohemen, Ch. G., 59

Pachner, A. R., Kantor, F. S., Mulac-Jericevic, B. and Atassi, M. Z., An immunodominant site of acetylcholine receptor in experimental myasthenia mapped with T lymphocyte clones and synthetic peptides, 199
Pals, S. T., see Facchetti, F., 277
Panagiotidi, C., see Gregoriadis, G., 237
Panyutich, A. V., see Voitenok, N. N., 77
Pawelec, G., Sayers, T. and Busch, F. W., Selective inhibition of interleukin 2 but not interferon-γ, tumour necrosis factor-α or granulocyte/macrophage colony stimulating factor secretion by human helper T cell clones after antigen-driven tolerization, 187
Peña, J., see Serrano, R., 311
Ponnappan, U., see Sauder, D. N., 111
Portetelle, D., see Depelchin, A., 69
Poruţiu, D., see Rus, H. G., 305
Pruett, S. B., see Smith, C., 15

Qu, X-m., see Okai, Y., 127

Rajczy, K., see Kramer, J., 83
Rauws, E. A. J., see Van Bohemen, Ch. G., 59
Rayfield, L. S., Smith, T. A., Andrews, S. J. and Bergmeier, L. A., Induction of experimental autoimmune thyroiditis in B cell-depleted mice, 21
Richardson, P., see Lowe, J., 103
Roboz, J. P., see Sei, Y., 223
Roldan, A., Charreau, E., Schillaci, R., Eugui, E. M. and Allison, A. C., Insulin-like growth factor-1 increases the mitogenic response of human peripheral blood lymphocytes to phytohemagglutinin, 5
Rowe, M., Comments by Dr. M. Rowe on hypothesis by Drs. Sulitzeanu and Anafi, 95
Rus, H. G., Niculescu, F., Poruţiu, D., Ghiurca, V. and Vlaicu, R., Cells carrying C5b-9 complement complexes in human atherosclerotic wall, 305

Saeki, T. and Nagasawa, S., Expression of the binding molecules for factor B and its fragment, Bb, of human complement on human monocytes after in vitro cultivation, 97
Sakurada, J. K., see Camargo, I. J. B., 213
Sander, B., see Andersson, U., 115
Sarin, P. S., see Sei, Y., 223
Sarkadi, B., see Tordai, A., 47
Sarmay, G., see Gergely, J., 1
Sauder, D. N., Ponnappan, U. and Cinader, B., Effect of age on cutaneous interleukin 1 expression, 111
Sautès, C., see Fridman, W. H., 249
Sayers, T., see Pawelec, G., 187
Schillaci, R., see Roldan, A., 5
Schlegel-Haueter, S. E. and Aebischer, F., Interleukin 1 induction of a serine esterase in a murine T cell line is inhibited by fetal calf serum, 35
Sei, Y., Tsang, P. H., Chu, F. N., Wallace, I., Roboz, J. P., Sarin, P. S. and Bekesi, J. G., Inverse relationship between HIV-1 p24 antigenemia, anti-p24 antibody and neutralizing antibody response in all stages of HIV-1 infection, 223
Seman, M., see Henry-Toulmé, N., 63
Serrano, R., Alonso, C., Solana, R., Monserrat, J., Muñoz, J. and Peña, J., Identification of a tumour factor inducing resistance to NK cell lysis, 311
Sihvola, M., see Hurme, M., 217
Sjögren, H. O., see Dohlsten, M., 29
Sjöholm, A. G., see Sturfelt, G., 231
Smith, C. and Pruett, S. B., Circadian variations of human lymphocytes are not responsible for contradictory or variable results in studies of IL-2 production, 15
Smith, T. A., see Rayfield, L .S., 21
Solana, R., see Serrano, R., 311
Stenszky, V., see Bodolay, E., 163
Sturfelt, G., Sjöholm, A. G. and Truedsson, L., Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes, 231
Sulitzeanu, D. and Anafi, M., EBV, molecular mimicry and rheumatoid arthritis: a hypothesis, 89
Suzuki, N., see Kanamori, H., 293
Szegedi, G., see Bodolay, E., 163
Szekeres-Bartho, J., see Najbauer, J., 317
Sánchez-Madrid, F., see Cabañas, C., 193

Takahashi, T., see Ishida, H., 323
Teillaud, J. L., see Fridman, W. H., 249
Tigyi, G. J., see Najbauer, J., 317
Tordai, A., Sarkadi, B., Görög, Gy. and Gárdos, G., Inhibition of the CD3-mediated calcium signal by protein kinase C activators in human T (Jurkat) lymphoblastoid cells, 47
Truedsson, L., see Sturfelt, G., 231
Tsang, P. H., see Sei, Y., 223
Tschopp, J., see Nabholz, M., 179
Turetskaya, R. L., see Voitenok, N. N., 77

Uhl, B., see Wolf, B., 121

Van Bohemen, Ch. G., Langenberg, M. L., Rauws, E. A. J., Oudbier, J., Weterings, E. and Zanen, H. C., Rapidly decreased serum IgG to *Campylobacter pylori* following elimination of *Campylobacter* in

histological chronic biopsy *Campylobacter*-positive gastritis, 59
Van den Oord, J. J., see Facchetti, F., 277
Vaughan, J. H., Comments by Dr. J. H. Vaughan on hypothesis by Drs. Sulitzeanu and Anafi, 95
Vlaicu, R., see Rus, H. G., 305
Voitenok, N. N., Misuno, N. I., Panyutich, A. V., Kolesnikova, T. and Turetskaya, R. L., Induction of tumor necrosis factor synthesis in human monocytes treated by transcriptional inhibitors, 77

Wallace, I., see Sei, Y., 223
Weterings, E., see Van Bohemen, Ch. G., 59
Wolf, B., Hauschildt, S., Uhl, B., Metzger, J., Jung, G. and Bessler, W. G., Localization of the cell activator lipopeptide in bone marrow-derived macrophages by electron energy loss spectroscopy (EELS), 121

Yamauchi, S., see Kanai, Y., 9
Yodoi, J., see Ishida, H., 323

Zanen, H. C., see Van Bohemen, Ch. G., 59
Zucato, M. R. L., see Camargo, I. J. B., 213